Perfectus Biomed Group and SweetBio Inc. have published a joint paper in Biomedical and Translational Science exploring the activity and efficiency of a novel bioengineered wound product (BWP) and its potential to help combat infection. Perfectus Biomed regularly support companies who produce products for chronic wound care, read more about our testing capabilities and how we can support your project.
Contamination, colonization and subsequent infection of wounds can significantly impede healing. SweetBio Inc. has bioengineered a commercially available new advanced wound product uniquely synthesizing gelatin, Manuka honey and hydroxyapatite into a solid sheet, called APIS®.
In vitro testing performed by Perfectus Biomed Group reported a significant reduction in both Gram-positive and Gram-negative bacteria (Staphylococcus aureus and Pseudomonas aeruginosa) recovered from APIS® versus the control materials and APIS® itself, indicating its antibacterial potential.
Speaking about the research Dr. Isaac Rodriguez, Co-Founder & Chief Science Officer of SweetBio Inc. said “We enjoyed working with Perfectus Biomed to perform this in vitro bacterial reduction evaluation on APIS® – our novel bioengineered wound product for the management of chronic and acute wounds. The publishing of this work in Biomedical and Translational Science is a key step to understanding the potential APIS® has to help manage the pathogenic burden of a wound.”
Further studies are planned to assess if APIS® also has the potential to be antimicrobial or serve as a microbial barrier to guard against infection of wounds.
Perfectus Biomed regularly work with clients on novel research and development and our expertise in writing and submitting journal articles and conference abstracts ensures that the wider scientific community benefit from the knowledge shared.
Speak to us today about our client focused approach to in vitro and ex vivo testing requirements and how we can elevate your research to the next level.